NEWS

Company news and the latest scientific findings

|

Mar 2023

ME THERAPEUTICS INC. Announces The Grant Of A Chinese Patent On Their Lead G-CSF Antibody Candidate

ME Therapeutics Inc., a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased

Check out our profile on SEDAR+

|

Oct 2025

ME THERAPEUTICS ADDED TO CSE25 INDEX

|

Sep 2025

ME THERAPEUTICS SECURES U.S. PATENT FOR LEAD CANDIDATE AND ADVANCES BROADER THERAPEUTIC PROGRAMS

|

May 2025

ME THERAPEUTICS RECEIVES SUPPORT TO ADVANCE mRNA THERAPEUTIC CANDIDATES FOR CANCER AND INFLAMMATORY DISEASE

|

Mar 2025

ME THERAPEUTICS ANNOUNCES IT HAS ENGAGED LUCOSKY BROOKMAN LLP TO EXPLORE A LISTING ON THE NASDAQ OR NYSE

|

Jan 2025

ME THERAPEUTICS ANNOUNCES THAT ITS FIRST THERAPEUTIC MRNA CANDIDATE SHOWS ENCOURAGING ANTI-CANCER EFFICACY IN VIVO

|

Oct 2024

ME THERAPEUTICS HOLDINGS INC. APPOINTS CHIEF BUSINESS OFFICER

|

Oct 2024

ME THERAPEUTICS HOLDINGS INC. PROVIDES RESEARCH AND DEVELOPMENT UPDATE AND CORPORATE UPDATE

|

Sep 2024

ME THERAPEUTICS ANNOUNCES THE START OF TESTING OF FIRST MRNA FORMULATIONS FROM NANOVATION THERAPEUTICS COLLABORATION

|

Jul 2024

ME THERAPEUTICS ANNOUNCES NEW COLLABORATION WITH NANOVATION THERAPEUTICS ON ADVANCED THERAPEUTIC MRNA DELIVERY TO MYELOID CELLS

|

May 2024

ME THERAPEUTICS HOLDINGS INC. ANNOUNCES THE ADDITION OF TWO NEW CLINICAL CONSULTANTS TO CONTINUE THE ADVANCEMENT OF OUR LEAD ANTI-G-CSF ANTIBODY CANDIDATE TOWARDS A FIRST-IN-HUMAN CLINICAL TRIAL

|

May 2024

ME THERAPEUTICS TO PRESENT AT INVESTOR CLUBHOUSE AT THE CANADIAN OPEN AND ATTEND THE 2024 BIO INTERNATIONAL CONVENTION FOR PARTNERING OPPORTUNITIES

|

Apr 2024

ME THERAPEUTICS ANNOUNCES UPCOMING PARTICIPATION IN THE 2024 BLOOM BURTON & CO HEALTH CARE CONFERENCE AND INTERVIEW ON CSE TV

|

Apr 2024

ME THERAPEUTICS ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT

|

Mar 2024

ME THERAPEUTICS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT AND PROVIDES CORPORATE UPDATE

|

Jan 2024

ME THERAPEUTICS HOLDINGS INC. PROVIDES CORPORATE UPDATES

|

Dec 2023

ME THERAPEUTICS HOLDINGS INC. ANNOUCES LISTING ON THE FRANKFURT STOCK EXCHANGE (FSE) AND THE COMPLETION OF ITS REDESIGNED WEBSITE

|

Dec 2023

ME THERAPEUTICS HOLDINGS INC. Provides An Overview And Update On Current Research And Development Programs

|

Oct 2023

ME THERAPEUTICS HOLDINGS INC. Receives Funding Support For Preclinical Testing Of Prodrug Candidates

|

Oct 2023

ME THERAPEUTICS HOLDINGS INC. Announces Listing And Trading Of Its Common Shares On The Canadian Securities Exchange

|

Mar 2023

ME THERAPEUTICS INC. Publishes Research On The Role Of G-CSF In Breast And Colorectal Cancer In Cancer Research Communications

|

Mar 2023

ME THERAPEUTICS INC. Announces The Grant Of A Chinese Patent On Their Lead G-CSF Antibody Candidate

Keep up to date by subscribing to our mailing list